Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide Journal Article

  


Authors: Bambury, R. M.; Rathkopf, D. E.
Article Title: Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide
Abstract: The approval of abiraterone and enzalutamide for the treatment of advanced castration-resistant prostate cancer heralded a paradigm shift in the management of this disease. Nevertheless, new and improved treatments are needed since the disease remains incurable for the majority of these patients. In this article, we review the biology of castration-resistant disease as well as emerging therapeutic compounds directed at the androgen receptor, including galeterone, VT-464, ARN-509, and ODM-201. Mechanisms of action, early clinical data, and ongoing clinical studies for these compounds are all reviewed. The need to find optimal sequencing and combination strategies as well as the need for predictive biomarkers of response to these agents is discussed. © 2016 Elsevier Inc.
Keywords: castration-resistant prostate cancer; arn-509; galeterone; vt-464; odm-201; bipolar androgen therapy
Journal Title: Urologic Oncology: Seminars and Original Investigations
Volume: 34
Issue: 8
ISSN: 1078-1439
Publisher: Elsevier Inc.  
Date Published: 2016-08-01
Start Page: 348
End Page: 355
Language: English
DOI: 10.1016/j.urolonc.2015.05.025
PROVIDER: scopus
PUBMED: 26162486
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84936797820&doi=10.1016%2fj.urolonc.2015.05.025&partnerID=40&md5=f8a42f6f207a779998cb590354059ee9
Notes: Review -- Export Date: 3 January 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Dana Elizabeth Rathkopf
    272 Rathkopf
  2. Richard Bambury
    34 Bambury
Related MSK Work